# Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

> **NCT01874340** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** AIN457

## Key facts

- **NCT ID:** NCT01874340
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients
- **Last updated:** 2015-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874340, "Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01874340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*